首页 | 本学科首页   官方微博 | 高级检索  
     

依那普利对冠心病患者血清CXCL16及高敏C反应蛋白浓度的影响
引用本文:罗劲勇,万书平. 依那普利对冠心病患者血清CXCL16及高敏C反应蛋白浓度的影响[J]. 岭南心血管病杂志, 2014, 0(2): 178-181
作者姓名:罗劲勇  万书平
作者单位:湖北省天门市第一人民医院心内科,湖北天门,431700
摘    要:目的 探讨依那普利治疗对冠状动脉粥样硬化性心脏病(冠心病)患者血清CXCL16及高敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)浓度的影响.方法 取98例冠心病患者血清,分为稳定型心绞痛组和急性冠脉综合征组,并给予常规治疗及联合依那普利治疗3周,比较其血清CXCL16及hs-CRP浓度与正常人的差异,进行组内及组间比较分析.结果 冠心病患者血清CXCL16及hs-CRP浓度显著升高,急性冠脉综合征组较稳定型心绞痛组更高,差异有统计学意义(P<0.05).联合依那普利治疗后急性冠脉综合征组及稳定型心绞痛组血清CXCL16及hs-CRP浓度较治疗前均显著降低,差异有统计学意义[CXCL16:(1.44±0.67)ng· mL-1 vs.(3.45±0.62)ng·mL-1,P<0.05; (1.86-±0.76)ng·mL-1 vs.(2.65±0.95)ng·mL-1,P<0.05. hs-CRP:(1.21±0.46)mg·L-1vs.(3.32±1.08)mg·L-1,P<0.05;(1.62±0.76)mg· L-1 vs.(2.25±1.02)mg·L-1,P<0.05];其疗效优于常规治疗组,且在急性冠脉综合征组效果更优,以降低血清CXCL16浓度效应更明显.结论 依那普利可能通过抑制炎症因子的释放及降低血清CXCL16浓度从而发挥对冠心病的治疗作用.

关 键 词:冠状动脉疾病  依那普利  CXCL16  高敏C反应蛋白  CXCL16

Effect of enalapril on serum concentrations of CXCL16 and high-sensitive C-reactive protein in patients with coronary heart disease
LUO Jing-yong,WAN Shu-ping. Effect of enalapril on serum concentrations of CXCL16 and high-sensitive C-reactive protein in patients with coronary heart disease[J]. South China Journal of Cardiovascular Diseases, 2014, 0(2): 178-181
Authors:LUO Jing-yong  WAN Shu-ping
Affiliation:(Department of Cardiology, Tianmen First People's Hospital, Tianmen, Hubei 431700, China)
Abstract:Objectives To explore the effect of enalapril treatment on serum concentrations of CXCL16 and high-sensitive C-reactive protein (hs-CRP) in patients with coronary heart disease. Methods Totally 98 patients with coronary heart disease,including stable angina peetoris (SAP) and acute coronary syndrome (ACS) groups, were signed into conventional therapy group and combined with enalapril therapy group. Their serum concentrations of CXCL16 and hs-CRP were compared and analyzed. Results Compared with healthy individuals, serum concentrations of CXCL16 and hs-CRP significantly increased in both SAP and ACS groups, especially higher in ACS group (P〈O.05). After treatment combined with enalapril for 3 weeks, serum concentrations of CXCL16 and hs-CRP significantly decreased in both groups related to untreated [CXCL16: (1.44±0.67) ng.mL-1 vs. (3.45±0.62) ng.mL-1, P〈0.05; (1.86±0.76) ng.mL-1 vs. (2.65± 0.95) ng.mL-1,P〈0.05, hs-CRP: (1.21±0.46) mg.L-1 vs. (3.32±1.08) mg-L-1,P〈0.05; (1.62±0.76) mg-L-1vs. (2.25 ±1.02)mg .L-1,P〈0.05]. The reduction effect was more obviously when combined with enalapril therapy, specifically in ACS group. Conclusions Enalapril treatment may inhibit the release of inflammatory eytokines and decrease serum concentrations of CXCL16, thus play a critical role in the therapy of coronary heart disease.
Keywords:coronary heart disease  enalapril  CXCL16  high-sensitive C-reactive protein
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号